Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy
(MedPage Today) -- Progression-free survival (PFS) improved in advanced HER2-mutant non-small cell lung cancer (NSCLC) when treatment started with trastuzumab deruxtecan (T-DXd; Enhertu) instead of pembrolizumab (Keytruda) and chemotherapy, a large...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.